Search
Avacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigationalAnti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV) is a rare (estimated incidence of 3 cases per 100,000 per year) form of "pauci-immune" systemic small-vessel vasculitis typified by the presence of ANCAs in th...
Nimesulide
go.drugbank.com/drugs/DB04743ApprovedWithdrawnNimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and...
Mixtures: FRENAG PLUS %1+%5 SPREY, 50 MLProducts: UL-FLAM, AINEDIX 1G/100 MLCalcium Phosphate
go.drugbank.com/drugs/DB11348ApprovedInvestigationalCalcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] .
Mixtures: TL-Select, TL-Select DHAProducts: CALCIO TABLETAS RECUBIERTAS X 600 MGGuaifenesin
go.drugbank.com/drugs/DB00874ApprovedInvestigationalVet approvedGuaifenesin possesses a storied history, having been originally formally approved by the US FDA in 1952 and continues to be one of very few - if not perhaps the only drug that is readily available and used as an expectorant . Since that ...
Mixtures: Sedalmex XL Flu, Ninjacof-XGProducts: Topco Mucus Relief, VICKS VAPOSYRUP 200 MG/15 ML EXPECTORANT SURUP 120 MLADX-10061
go.drugbank.com/drugs/DB05419ExperimentalADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
QazCovid-in
go.drugbank.com/drugs/DB16441InvestigationalIt demonstrated high efficacy, safety, and immunogenicity at 96% in initial Phase I and II trials (NCT04530357), and will now be undergoing upcoming Phase III trials[L30633, L30638].
Fidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigational[L46691] Hemophilia B is a rare X-linked genetic disorder characterized by abnormal coagulation due to dysfunctional coagulation factor IX with a male incidence estimated to be 1 in 30,000 male births … [L49469] This approval was based on positive results demonstrated in the open-label, single-arm Phase 3 BENEGENE-2 study, where the annualized bleeding rate (ABR) was observed to be 1.3 for the 12 months
Riferminogene pecaplasmid
go.drugbank.com/drugs/DB06394InvestigationalRiferminogene pecaplasmid (non-viral fibroblast growth factor 1; NV1FGF) is a recombinant DNA plasmid in a pCOR backbone allowing expression of human FGF1.
Curcuma xanthorrhiza oil
go.drugbank.com/drugs/DB11265ApprovedNutraceuticalCurcuma xanthorrhiza oil is extracted from Curcuma xanthorrhiza Roxb., a member of the ginger family (Zingiberaceae) that is widely distributed in the region of Southeastern Asia . Curcuma xanthorrhiza is also known as Javanese Turmeric ...
Phenserine
go.drugbank.com/drugs/DB04892InvestigationalIf this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD.